A Phase 2 interventional study of CKD-495 75mg and CKD-495 150mg in Gastritis, sponsored by Chong Kun Dang Pharmaceutical. Completed at 16 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2018-10-31.
Sponsored by Chong Kun Dang Pharmaceutical · Phase 2, Interventional, and Treatment
Among 32 studies in Gastritis with a site in Korea, Republic of — 3 open to participants now, 3 under way, none of them phase 3. Gastritis · Korea, Republic of.
Among the 32 studies in Gastritis with a site in Korea, Republic of, this one is the 12th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2018, is one of 4 in phase 2, and was the 15th registered.
135 studies on the registry are indexed under Gastritis; 23 are open to participants now.
Browse Gastritis studies →3 of the 32 studies in Gastritis with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19–75
Korea Otsuka Pharmaceutical Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Addpharma Inc. · Sites in Korea, Republic of
Ages 19–50 · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 11 Gastritis studies recruiting now, 6 (55%) set no upper age limit and 5 (45%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 250 is above the median of 200 across 97 interventional studies indexed under Gastritis.
Median enrollment 242 across the 25 interventional studies, 585 across the 7 observational. Of the 23 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 32 have an industry lead sponsor. The 10 most frequent:
Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 15 are open to participants now.
Chong Kun Dang Pharmaceutical has 3 studies filed under Gastritis — fewer than ten, so there is no comparison to draw.
1 of the studies in Gastritis with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07717775Addpharma Inc.A Study of Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy Adults | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies in Gastritis with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To Evaluate the Efficacy and Safety of CKD-495
A Phase 2, Multi-center, Randomized, Double-blind, Parallel-group Trial to Evaluate the Efficacy and Safety of CKD-495 in Patients with Acute and Chronic Gastritis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients assigned to this group are treated with CKD-495 75mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 150mg, ,Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
Drug: CKD-495 75mg · Drug: Placebo of the CKD-495 150mg · Drug: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg · Drug: Placebo of the Rebamipide 100mg
Patients assigned to this group are treated with CKD-495 150mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
Drug: CKD-495 150mg · Drug: Placebo of the CKD-495 75mg · Drug: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg · Drug: Placebo of the Rebamipide 100mg
Patients assigned to this group are treated with 4 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
Drug: Placebo of the CKD-495 75mg · Drug: Placebo of the CKD-495 150mg · Drug: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg · Drug: Placebo of the Rebamipide 100mg
Patients assigned to this group are treated with Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab, and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of the Rebamipide 100mg Tab.)
Drug: Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg · Drug: Placebo of the CKD-495 75mg · Drug: Placebo of the CKD-495 150mg · Drug: Placebo of the Rebamipide 100mg
Patients assigned to this group are treated with Rebamipide 100mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.)
Drug: Rebamipide 100mg · Drug: Placebo of the CKD-495 75mg · Drug: Placebo of the CKD-495 150mg · Drug: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
CKD-495 75mg Tab.
CKD-495 150mg Tab.
Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
Rebamipide 100mg Tab.
Placebo of the CKD-495 75mg Tab.
Placebo of the CKD-495 150mg Tab.
Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
Placebo of the Rebamipide 100mg Tab
Improvement rate of gastric erosion
50% decreased on erosive grade
Time frame: 14days after drug administrations
cure rate of gastric erosion
0 erosion
Time frame: 14days after drug administrations
Improvement rate of symptoms
50% decreased on the Subjective Symptoms total score
Time frame: 14days after drug administrations
Improvement rate of gastric edema
50% decreased on the Edema grade
Time frame: 14days after drug administrations
Improvement rate of gastric erythema
50% decreased on the Erythema grade
Time frame: 14days after drug administrations
Improvement rate of gastric hemorrhage
50% decreased on the Hemorrhage grade
Time frame: 14days after drug administrations
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2018 to primary completion in Oct 2018, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chong Kun Dang Pharmaceutical →